https://www.sciencedirect.com/science/article/pii/S0924857920303423
Belgische studie over Hydroxychloroquine.
Of 8075 patients with complete discharge data on 24th of May and diagnosed before the 1st of May, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, the mortality was lower in the HCQ group compared to the no-HCQ group (adjusted hazard ratio
0.684, 95% confidence interval [CI] 0.617–0.758).
Conclusions
Compared to supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients with COVID-19 diagnosed and treated early or later after symptom onset.
Andere studies:
https://www.sciencedirect.com/science/article/pii/S1477893920302817?via=ihub
Conclusion
Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.
Nog een studie:
https://www.ejinme.com/article/S0953-6205(20)30335-6/fulltext
Conclusions
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.
Als er diepgaande studies gaan uitkomen over de werkzaamheid van Hydroxychloroquine als drug voor de behandeling van Covid. En die tonen meer en meer aan dat het een positief effect heeft. Is dit nog een exta win voor Trump.